Rivus throws down mid-stage liver fat data on quest to climb NASH mountainnews2022-02-09T14:36:57+00:00February 9th, 2022|FierceBiotech|
Chasing Novartis and Roche, Ventus banks $140M to take inflammatory disease drug into the clinicnews2022-02-09T13:14:22+00:00February 9th, 2022|FierceBiotech|
GSK kills one of Barron’s early darlings, axing two synthetic lethal programs and Epizyme pactnews2022-02-09T11:17:24+00:00February 9th, 2022|FierceBiotech|
GSK kills one of Barron’s early darlings, axing 2 synthetic lethal programs and Epizyme pactnews2022-02-09T11:17:24+00:00February 9th, 2022|FierceBiotech|
Chutes & Ladders—Editas fires chief medical officer without explanationnews2022-02-08T22:11:04+00:00February 8th, 2022|FierceBiotech|
Biotech IPOs in the current market environment? Experts say it’s ‘a bit silly, if not suicidal’news2022-02-08T21:47:52+00:00February 8th, 2022|FierceBiotech|
With $1.7T in the coffers, biopharma M&A expected to be ‘a different animal’ in 2022news2022-02-08T19:11:27+00:00February 8th, 2022|FierceBiotech|
Axsome’s migraine drug finally slated for FDA inspection but investors really want to know about stalled depression therapynews2022-02-08T16:59:10+00:00February 8th, 2022|FierceBiotech|
Axsome’s migraine drug finally slated for FDA inspection, but investors want to know about stalled depression therapynews2022-02-08T16:59:10+00:00February 8th, 2022|FierceBiotech|
Ovid pens deal to offload twice-failed former lead program, positioning Healx to write new chapter in fragile Xnews2022-02-08T14:01:03+00:00February 8th, 2022|FierceBiotech|
